Understanding how a protein called LARP1 controls cell processes in cancer
Translation regulation by molecular switch RNA-binding protein LARP1
This work explores how a key protein, LARP1, helps cells decide which instructions to follow, which is important for understanding cancers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11143845 on NIH RePORTER |
What this research studies
Our cells constantly receive signals from their environment, and proteins like LARP1 act as crucial switches, turning on or off the production of other proteins based on these signals. In cancers, these switches can malfunction, leading to uncontrolled cell growth and other problems. This research aims to uncover the precise molecular details of how LARP1 works as a switch, changing its shape and interactions to guide cell decisions. By understanding these fundamental mechanisms, we hope to identify new ways to correct faulty cell processes. This knowledge could pave the way for new strategies to treat various cancers.
Who could benefit from this research
Good fit: Patients with various types of cancer could potentially benefit from future treatments developed from this fundamental understanding.
Not a fit: Patients seeking immediate new treatments or direct clinical trial participation would not directly benefit from this early-stage basic science research.
Why it matters
Potential benefit: If successful, this work could reveal new targets for developing medications that correct faulty cell processes in cancer.
How similar studies have performed: While the general concept of RNA-binding proteins is known, the specific principles guiding how these proteins act as molecular switches are surprisingly understudied, making this a novel area of focus.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Berman, Andrea J. — University of Pittsburgh at Pittsburgh
- Study coordinator: Berman, Andrea J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.